{'fraction_non_alphanumeric': 0.028700906344410877, 'fraction_numerical': 0.0015105740181268882, 'mean_word_length': 6.0855614973262036, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Efficient Overcoming of Blood–Brain Barrier by Functionalized Selenium Nanoparticles to Treat Glioma

The blood–brain barrier (BBB) can block drug delivery into the human brain, and thus remains the primary obstacle in the efficient treatment of glioma. Herein, Polyporus Amboinensis Lam (PAL)‐functionalized selenium nanoparticles (SeNPs) (hereafter referred to as PAL‐SeNPs) are fabricated as a cancer‐targeted nanosystem to antagonize the BBB and thus enhance anti‐glioma ability. The robust synthesis of PAL‐SeNPs confers the nanosystem with high‐stability and the ideal size for efficient endocytosis in glioma cells. The structure similarity of PAL with αvβ3 integrin, which is overexpressed on glioma cells, increases the selectivity between glioma cells and normal gliocytes via the PAL/αvβ3 integrin‐mediated targeting effect, and displays a favorable anti‐glioma effect by hastening m‐TOR‐mediated cell apoptosis. Pharmacokinetics analysis demonstrates that PAL‐SeNPs improves the half‐life of SeNPs in blood and ensures their sufficient accumulation in the brain. PAL‐SeNPs facilitate effective transportability across the BBB and exhibit superior permeability into glioma tumor spheroid. Taken together, this study provides a robust strategy of using SeNPs to overcome the BBB for enhanced anti‐glioma treatment.